financetom
Business
financetom
/
Business
/
Update: Logan Energy Up 6.5% As Posts Quarter-Over-Quarter Increase In Adjusted Funds Flow In Q4, Upsizes Credit Facility; National Bank Says Program Advancing Positively
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Logan Energy Up 6.5% As Posts Quarter-Over-Quarter Increase In Adjusted Funds Flow In Q4, Upsizes Credit Facility; National Bank Says Program Advancing Positively
Mar 19, 2024 7:47 AM

10:24 AM EDT, 03/19/2024 (MT Newswires) -- Logan Energy Corp. ( LOECF ) , which fell 2.5% to near 52-week lows yesterday, overnight Monday reported fourth-quarter 2023 adjusted funds flow of $15.4 million, up 198% from the third quarter of 2023.

The company achieved production of 7,515 barrels of oil equivalent per day on average for the fourth quarter of 2023, up 39% from the previous quarter.

As of Dec. 31, 2023, Logan's proved developed producing (PDP) reserves are 9.9 million boe, total proved (TP) reserves are 43.3 million boe and total proved plus probable (TPP) reserves are 74.8 million boe.

The before-tax net present value (NPV) of reserves, discounted at 10% was about $51.3 million on a PDP basis, $192.6 million on a TP basis and $393.0 million on a TPP basis.

In addition, the company's lender increased the authorized borrowing amount available under the credit facility to $50.0 million from $15.0 million, effective March 18.

Logan at last look gained 6.5% in early Tuesday trading.

Logan's cash flow per share of $0.03 beat National Bank of Canada's forecast of $0.02 while its production also exceeded the bank's forecast of 6,609 boe/d.

National Bank noted that Logan's program continues to advance positively, with three recently drilled Pouce Coupe wells outperforming type-curve by 5%-10%.

"A strong year-end update from the company, indicative of the momentum and value creation of its program, which we expect should continue to yield outperformance and upside," National Bank said.

The bank gave Logan an outperform rating with a $1.50 price target.

Price: 0.82, Change: +0.05, Percent Change: +6.49

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Street Color: Lyft to Roll Out Driverless Rides This Summer
--Street Color: Lyft to Roll Out Driverless Rides This Summer
Mar 20, 2025
02:32 PM EDT, 03/20/2025 (MT Newswires) -- Price: 11.72, Change: -0.01, Percent Change: -0.04 ...
Blake Lively seeks to end Justin Baldoni's 'vengeful' $400 million defamation lawsuit
Blake Lively seeks to end Justin Baldoni's 'vengeful' $400 million defamation lawsuit
Mar 20, 2025
* Lively says Baldoni 'weaponizing' defamation case * 'It Ends With Us' co-stars allege competing smear campaigns * Baldoni's lawyers not immediately available for comment (Recasts first paragraph; adds details from Lively court filing, lawyers' comments, paragraphs 2-3, 11-15) By Jonathan Stempel NEW YORK, March 20 (Reuters) - Actress Blake Lively asked a U.S. judge on Thursday to dismiss actor...
Mariah Carey wins copyright lawsuit over 'All I Want for Christmas Is You'
Mariah Carey wins copyright lawsuit over 'All I Want for Christmas Is You'
Mar 20, 2025
* Judge rules songs not objectively similar for copyright case * Carey's song tops Billboard Hot 100 every holiday season since 2019 * Songwriters ordered to pay part of Carey's legal fees By Blake Brittain March 20 (Reuters) - Pop singer Mariah Carey defeated a lawsuit claiming she illegally copied elements of her holiday megahit All I Want for Christmas...
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders
Mar 20, 2025
Monte Rosa Therapeutics Inc ( GLUE ). on Thursday revealed clinical results from its MRT-6160 Phase 1 single ascending dose/multiple ascending dose (SAD/MAD) study. The study objectives were to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics, including VAV1 degradation and its impact on T and B cell function following ex vivo stimulation. Results demonstrated sustained, dose-dependent VAV1 degradation of greater than...
Copyright 2023-2026 - www.financetom.com All Rights Reserved